Keytruda gaining edge over competitors in kidney cancer, says analyst

18 February 2019

Merck & Co’s (NYSE: MRK) abstract presentation regarding KEYNOTE-426 trial at 2019 Genitourinary Cancers Symposium (ASCO GU) has confirmed that its Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with fellow US pharma giant Pfizer’s (NYSE: PFE) Inlyta (axitinib), a tyrosine kinase inhibitor, can significantly improve clinical outcomes for renal cancer patients.

Findings from the first interim analysis showed Keytruda in combination with axitinib reduced the risk of death by 47% “significantly improving overall survival (OS) compared to sunitinib (HR=0.53 [95% CI, 0.38-0.74]; p<0.0001).

Also last week, the US Food and Drug Administration accepted under Priority Review status Merck's supplemental marketing application seeking approval for Keytruda plus Inlyta for the treatment of advanced renal cell carcinoma in a first-line setting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK